The global Multiple System Atrophy (MSA) Therapeutics Market, currently valued at USD 137.3 million in 2023, is expected to witness significant growth over the next decade. According to market projections, the MSA therapeutics market is anticipated to expand at a compound annual growth rate (CAGR) of 4.4% during the forecast period of 2023 to 2033, reaching an estimated USD 211.1 million by 2033.
This market expansion is being driven by technological advancements in the healthcare sector, which are contributing to the development of innovative therapies for managing and treating MSA, a rare but rapidly progressing neurodegenerative disorder. The increasing focus on early diagnosis, along with ongoing research in treatment options, is expected to drive market growth.
Key Market Insights:
- The MSA therapeutics market is valued at US$ 137.3 million in 2023.
- The market is projected to expand at a 4.4% CAGR from 2023 to 2033.
- Market size is expected to reach US$ 211.1 million by 2033.
Growth Factors:
- Rising awareness of multiple system atrophy and advancements in diagnostics.
- Technological innovations in therapeutic development.
- Increasing investments in research and development for rare neurological disorders.
The Multiple System Atrophy Therapeutics Market is set for a steady trajectory of growth, driven by healthcare advancements and a growing need for effective treatment solutions. The industry is expected to benefit from ongoing collaborations between pharmaceutical companies, research institutes, and healthcare providers aimed at improving the quality of life for MSA patients.
Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.
The slowness of movement, tremors, rigidity, and incoordination are the first signs and multiple system atrophy symptoms. The parkinsonian type (MSA-P) with primary symptoms similar to Parkinson’s disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia is the most prominent multiple system atrophy symptoms of evaluation.
Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson’s disease. Autonomic testing (such as blood pressure control and heart rate control), assessment of bladder function, and neuroimaging such as an MRI (magnetic resonance imaging) or PET scan are examples of diagnostic tests.
Competitive Landscape
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
- In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced new milestones in potential therapeutic approaches for ALS.
- In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, and infectious and autoimmune diseases.
Key Companies Profiled : Biohaven Pharmaceuticals, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; AstraZeneca plc; Theravance Biopharma, Inc.; Merck & Co.; Neuropore Therapies Inc; Newron Pharmaceuticals SpA; ProMIS Neurosciences Inc; Stealth BioTherapeutics Corp; Chelsea Therapeutics International, Ltd.
Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey
Multiple System Atrophy (MSA) Therapeutics Market by Type:
- Parkinsonian
- Cerebellar
Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
Multiple System Atrophy (MSA) Therapeutics Market by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
